Search
for
Sort by
Research 181–210 of 1000+
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Alopecia Universalis: Never Give Up?
- Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
- Randomized Controlled Trial Study to Evaluate the Efficacy of Combination Therapy with Diphenylcyclopropenone and Platelet-Rich Plasmain Alopecia Areaata
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis
- Study of effect of topical mometasone with intralesional platelet-rich plasma versus topical mometasone alone in the treatment of alopecia areata
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Objective outcome measures: Collecting meaningful data on alopecia areata
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata
- Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- A clinical study on alopecia areata
- Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
- Efficacy and safety of tofacitinib in patients with alopecia areata